Venturi Wealth Management LLC Acquires 8,611 Shares of AbbVie Inc. $ABBV

Venturi Wealth Management LLC increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 9.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 98,919 shares of the company’s stock after purchasing an additional 8,611 shares during the period. AbbVie makes up approximately 1.0% of Venturi Wealth Management LLC’s holdings, making the stock its 25th largest position. Venturi Wealth Management LLC’s holdings in AbbVie were worth $21,514,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Chelsea Counsel Co. acquired a new position in shares of AbbVie during the third quarter worth approximately $26,000. Litman Gregory Wealth Management LLC bought a new position in AbbVie during the fourth quarter worth $28,000. Westend Capital Management LLC acquired a new position in AbbVie during the 4th quarter valued at $29,000. Imprint Wealth LLC boosted its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX bought a new stake in AbbVie in the 3rd quarter valued at $31,000. Institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

AbbVie Price Performance

AbbVie stock opened at $251.52 on Friday. The business has a 50 day simple moving average of $215.16 and a 200 day simple moving average of $219.18. The company has a market capitalization of $444.38 billion, a PE ratio of 123.90, a price-to-earnings-growth ratio of 0.77 and a beta of 0.32. AbbVie Inc. has a one year low of $181.73 and a one year high of $253.35.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the business posted $2.46 earnings per share. The business’s revenue was up 12.4% compared to the same quarter last year. Equities analysts anticipate that AbbVie Inc. will post 14.28 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s payout ratio is 340.89%.

Analysts Set New Price Targets

Several research firms have recently issued reports on ABBV. William Blair restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. Morgan Stanley lifted their price objective on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Finally, Canaccord Genuity Group raised their target price on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.81.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.